Business
OncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility
OncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility\n\nOncBioMune's Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility\n\nBATON ROUGE, LA--(Marketwired - June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that the Company's licensed male fertility product Andfrt® demonstrated a clinically meaningful benefit in treating asthenozoospermia, a medical condition defined by abnormal sperm motility.As disclosed on May 30, 2017, the Mexican Ministry of Health (MoH) recently authorized the commercialization of Andfrt®. Upon the approval, OncBioMune, through its 100%-owned Mexican subsidiary, immediately initiated the launch of Andfrt®, joining Bekunis® for constipation and Cirkused® for stress as products marketed by OncBioMune in the Mexican market.In support of the MoH authorization, OncBioMune Mexico conducted an in-house clinical trial of Andfrt®, with the goal of evaluating the effect of the product on Mexican males with asthenozoospermia. In the 25-patient study (not statistically powered), the total count, mobility and morphology of the sperm had significant improvements in all subjects, as shown through analysis of variance (final visit) and multi-analysis of variance for repeated measurements (all visits).\"The results look very promising, especially given to the lack of competing available products versus Andfrt®. We are very much looking forward to treating our patients in short term with the new product,\" said Dr. Arturo Ramirez Muciño, a recognized urologist in Mexico.\"As Dr. Muciño succinctly points out, there is a great need for a product like Andfrt® in Mexico for the management of persistent asthenozoospermia,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"The product is already the leading male fertility product in Europe and we believe it will achieve similar success in Mexico under our brand, which is why we are moving expeditiously to distribute it to urologists and pharmacies across the country.\"OncBioMune has rights to A...